These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15526004)

  • 21. Association of rheumatoid factor production with FcgammaRIIIa polymorphism in Taiwanese rheumatoid arthritis.
    Chen JY; Wang CM; Wu JM; Ho HH; Luo SF
    Clin Exp Immunol; 2006 Apr; 144(1):10-6. PubMed ID: 16542359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept?
    Murdaca G; Gulli R; Spanò F; Mandich P; Puppo F
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S7-S10. PubMed ID: 25381983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fcγ receptor 3B polymorphism is associated with hypersensitivity reactions to adalimumab in Japanese patients with rheumatoid arthritis.
    Tsukamoto M; Kameda H; Ohshige T; Kaneko Y; Yoshimoto K; Suzuki K; Takeuchi T
    Mod Rheumatol; 2017 Sep; 27(5):778-781. PubMed ID: 27830964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on the association of Fc gamma receptor IIA, IIB, IIIA and IIIB polymorphisms with rheumatoid arthritis in the Japanese: evidence for a genetic interaction between HLA-DRB1 and FCGR3A.
    Kyogoku C; Tsuchiya N; Matsuta K; Tokunaga K
    Genes Immun; 2002 Dec; 3(8):488-93. PubMed ID: 12486608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FCGR2A single nucleotide polymorphism confers susceptibility to childhood-onset idiopathic nephrotic syndrome.
    Rossi GM; Bonatti F; Adorni A; Alberici F; Bodria M; Bonanni A; Ghiggeri GM; Martorana D; Vaglio A
    Immunol Lett; 2018 Jan; 193():11-13. PubMed ID: 29155175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors.
    Montes A; Perez-Pampin E; Joven B; Carreira P; Fernández-Nebro A; Del Carmen Ordóñez M; Navarro-Sarabia F; Moreira V; Vasilopoulos Y; Sarafidou T; Caliz R; Ferrer MA; Cañete JD; de la Serna AR; Magallares B; Narváez J; Gómez-Reino JJ; Gonzalez A
    Pharmacogenomics; 2015; 16(4):333-45. PubMed ID: 25823782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC; Song GG
    Rheumatol Int; 2014 Oct; 34(10):1409-15. PubMed ID: 24728031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additive effect of polymorphisms in the IL-6, LTA, and TNF-{alpha} genes and plasma fatty acid level modulate risk for the metabolic syndrome and its components.
    Phillips CM; Goumidi L; Bertrais S; Ferguson JF; Field MR; Kelly ED; Mehegan J; Peloso GM; Cupples LA; Shen J; Ordovas JM; McManus R; Hercberg S; Portugal H; Lairon D; Planells R; Roche HM
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1386-94. PubMed ID: 20080841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis.
    Dávila-Fajardo CL; van der Straaten T; Baak-Pablo R; Medarde Caballero C; Cabeza Barrera J; Huizinga TW; Guchelaar HJ; Swen JJ
    Pharmacogenomics; 2015; 16(4):373-81. PubMed ID: 25823785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta-analysis.
    Lee YH; Song GG
    Int J Rheum Dis; 2023 Jul; 26(7):1295-1304. PubMed ID: 37114884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
    Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases.
    Weisman MH; Paulus HE; Burch FX; Kivitz AJ; Fierer J; Dunn M; Kerr DR; Tsuji W; Baumgartner SW
    Rheumatology (Oxford); 2007 Jul; 46(7):1122-5. PubMed ID: 17470434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis.
    Fabris M; Tolusso B; Di Poi E; Assaloni R; Sinigaglia L; Ferraccioli G
    J Rheumatol; 2002 Sep; 29(9):1847-50. PubMed ID: 12233877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor necrosis factor (TNF) and TNFR1 polymorphisms are not risk factors for rheumatoid arthritis in a Mexican population.
    Cadena-Sandoval D; Alemán-Ávila I; Barbosa-Cobos RE; Becerril-Mendoza LT; Fragoso JM; Ramírez-Bello J
    Mol Biol Rep; 2018 Jun; 45(3):227-232. PubMed ID: 29404828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis.
    Schotte H; Schlüter B; Drynda S; Willeke P; Tidow N; Assmann G; Domschke W; Kekow J; Gaubitz M
    Ann Rheum Dis; 2005 Apr; 64(4):575-81. PubMed ID: 15345504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents.
    Tutuncu Z; Kavanaugh A; Zvaifler N; Corr M; Deutsch R; Boyle D
    Arthritis Rheum; 2005 Sep; 52(9):2693-6. PubMed ID: 16142749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor necrosis factor-alpha promoter -308 A/G polymorphism and rheumatoid arthritis susceptibility: a metaanalysis.
    Lee YH; Ji JD; Song GG
    J Rheumatol; 2007 Jan; 34(1):43-9. PubMed ID: 17143972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
    Dávila-Fajardo CL; Márquez A; Pascual-Salcedo D; Moreno Ramos MJ; García-Portales R; Magro C; Alegre-Sancho JJ; Balsa A; Cabeza-Barrera J; Raya E; Martín J
    Pharmacogenet Genomics; 2014 Jan; 24(1):1-5. PubMed ID: 24253594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are glucocorticoids a consistent risk factor for infections in rheumatoid arthritis patients under treatment with methotrexate and etanercept?
    Luzi G; Laganà B; Salemi S; Di Rosa R
    Clin Ter; 2009; 160(2):121-3. PubMed ID: 19452100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.